Blueprint Medicines stock hits all-time high at 129.49 USD

Blueprint Medicines Corp (NASDAQ:BPMC) stock has reached an all-time high, hitting a price of 129.49 USD. According to InvestingPro data, the stock’s RSI indicates overbought territory, with the price now trading just 1% from its 52-week high of 128.78 USD. This milestone reflects a significant upward trend for the biotechnology company, which has experienced a 1-year return of 10.87%. The stock’s impressive performance includes a remarkable 47% gain over the past six months, with InvestingPro analysis suggesting the stock is currently trading above its Fair Value. Investors considering BPMC should note that while the company maintains strong liquidity with a current ratio of 2.8, analysts expect net income to decline this year. As Blueprint Medicines continues to innovate in the field of precision medicine, this all-time high underscores its growing influence and success in the competitive biotech sector. The company has achieved impressive revenue growth of 99% in the last twelve months, though it’s worth noting that InvestingPro analysis reveals 12 additional key insights about BPMC’s financial health and market position.

In other recent news, Blueprint Medicines has announced its acquisition by Sanofi (NASDAQ:SNY) in a transaction valued at approximately $9.5 billion. The agreement involves a cash purchase of $129 per share, along with contingent value rights (CVRs) related to the pipeline asset BLU-808. This acquisition aims to enhance Sanofi’s portfolio in rare immunological diseases and expand its early-stage pipeline in immunology. Following this announcement, Citi upgraded Blueprint Medicines’ stock rating to Neutral, aligning its price target with the acquisition offer. Conversely, Citizens JMP, TD Cowen, and JPMorgan downgraded their ratings, citing the acquisition’s impact on stock performance and the terms of the agreement. The deal includes a potential additional payment of $6 per share tied to future development and regulatory milestones for BLU-808. Blueprint Medicines’ Ayvakit, the only approved medication for advanced and indolent systemic mastocytosis, reported net revenues of nearly $150 million in the first quarter of 2025, marking a significant growth over the previous year. The acquisition is anticipated to close in the third quarter of 2025, pending regulatory approvals and other conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.